Previous 10 | Next 10 |
3 Reddit Penny Stocks to Watch in May 2021 As May goes on, there are hundreds of penny stocks on Reddit that could be worth watching. However, just because a company is a Reddit penny stock , does not mean that it is worth buying. Rather, investors need to make sure to do their due ...
Akebia Therapeutics, Inc. (AKBA) Q1 2021 Earnings Conference Call May 10, 2021 09:00 ET Company Participants Kristen Sheppard - Senior Vice President, Investor Relations John Butler - Chief Executive Officer David Spellman - Chief Financial Officer Conference Call Participants Ally Bratzel - ...
Akebia (AKBA): Q1 GAAP EPS of -$0.45 misses by $0.08.Revenue of $52.3M (-40.9% Y/Y) beats by $10.59M.Cash, cash equivalents and available-for-sale securities of $272.8M. The Company expects its cash resources to fund its current operating plan beyond the expected U.S. launch of vada...
Akebia Reports First Quarter 2021 Financial Results and Highlights Recent Company Milestones - Vadadustat New Drug Application (NDA) submitted to the U.S. Food and Drug Administration (FDA) - Results of global Phase 3 programs for vadadustat published in New England Journal ...
Akebia Therapeutics (AKBA) announces that the New England Journal of Medicine ((NEJM)) has published the results of the global Phase 3 clinical program of vadadustat for the treatment of anemia due to chronic kidney disease ((CKD)) in adult patients.Vadadustat, an investigation...
New England Journal of Medicine Publishes Results of Global Phase 3 Clinical Program of Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease Program Evaluated the Safety and Efficacy of Vadadustat in Adult Patients with Anemia Due to CKD on Dialysis and Not on Di...
Akebia Therapeutics to Report First Quarter 2021 Financial Results and Discuss Recent Business Highlights PR Newswire CAMBRIDGE, Mass. , April 28, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose...
Akebia Therapeutics to Present at 20th Annual Needham Virtual Healthcare Conference PR Newswire CAMBRIDGE, Mass. , April 12, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of peo...
SOS (SOS) +36%.Titan Medical (TMDI) +25%.CBAK Energy Technology (CBAT) +21%.Altimeter Growth (AGCUU) +18%.CA Healthcare Acquisition (CAHCU) +16%.TransMedics (TMDX) +16%. as FDA Advisory Panel has issued a favorable vote in support of approval of the OCS Heart System.Altimeter Growth (AGC...
After FibroGen (FGEN) shares collapsed 28% after-hours in reaction to certain disclosures of safety analyses from the roxadustat program, the FDA has tentatively scheduled a Cardiovascular and Renal Drug Advisory Committee ((CRDAC)) on July 15, 2021 to review the New Drug ...
News, Short Squeeze, Breakout and More Instantly...
Akebia Therapeutics Inc. Company Name:
AKBA Stock Symbol:
NASDAQ Market:
Akebia Therapeutics Inc. Website:
2024-03-28 14:00:02 ET Ed Arce from H.C. Wainwright issued a price target of $6.00 for AKBA on 2024-03-28 12:08:00. The adjusted price target was set to $6.00. At the time of the announcement, AKBA was trading at $1.98. The overall price target consensus is at $7.00 with...
Wednesday, the FDA approved Akebia Therapeutics Inc (NASDAQ:AKBA) Vafseo (vadadustat) tablets for anemia due to chronic kidney disease (C...
2024-03-28 13:30:02 ET H.C. Wainwright analyst issues BUY recommendation for AKBA on March 28, 2024 12:08PM ET. The previous analyst recommendation was Buy. AKBA was trading at $2.0093 at issue of the analyst recommendation. The overall analyst consensus : BUY. Curre...